RxDoctor Payments Data

Paolo Troia-Cancio, MD

Internal Medicine · Elk Grove, CANPI 1538141619

Payments from drug & device makers

$288,951in general payments, 2019–2025

Across 269 payments — averaging $1074.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$171K
  • Viiv Healthcare Company$93K
  • Merck$21K
  • Theratechnologies Inc.$3K
  • Johnson & Johnson$28

What the payments were for

  • Consulting fees$24,2708%
  • Speaking & faculty fees$225,26678%
  • Travel & lodging$36,89813%
  • Food & beverage$2,4881%
  • Education$280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead184$170,925
Viiv Healthcare Company54$93,398
Merck25$21,224
Theratechnologies Inc.5$3,375
Johnson & Johnson1$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$288,951 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$139,171
Medicare patients
420
Services billed
2,597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala77$345,171
TriumeqAbacavir/Dolutegravir/Lamivudi53$200,203
TivicayDolutegravir Sodium60$171,208
PromactaEltrombopag Olamine12$149,805
EliquisApixaban125$138,635
DescovyEmtricitabine/Tenofov Alafenam47$122,365
OzempicSemaglutide103$116,136
OdefseyEmtricitab/Rilpiviri/Tenof Ala29$96,689
CabenuvaCabotegravir/Rilpivirine14$75,290
JardianceEmpagliflozin59$70,534
DovatoDolutegravir Sodium/Lamivudine23$67,473
PifeltroDoravirine33$65,669
RybelsusSemaglutide44$64,635
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf14$63,810
TrulicityDulaglutide55$57,949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq, Tivicay, Cabenuva, Dovato, Juluca$93,398$615,248179 claims
GileadBiktarvy, Descovy$170,925$467,536124 claims
Johnson & JohnsonPrezcobix, Xarelto$28$84,39946 claims
MerckPifeltro$21,224$65,66933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Elk Grove

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →